As Nova Scotia’s life sciences sector has grown and evolved, BioNova has grown along with it, and we felt it was time to reflect that growth. In the last year we’ve experienced a lot of changes with the implementation of BioNova’s Growth Plan and will continue to see changes as we move towards building a bigger and better ecosystem to grow the life sciences in Nova Scotia. When we made these changes, we realized that our brand elements didn’t express us quite as well as they used to. It was time for a brand refresh to reflect who we are today and to symbolize our dynamic future. We will be discussing our next steps and opportunities for growth for BioNova and for the sector at BioPort Atlantic in two weeks time on October 25-26. If you haven’t already registered yet, I encourage you to do so as these are discussions you will not want to miss! In the upcoming months we have to update all of our collaterals, marketing literature, online presence, etc. with our new logo. We are aware that changing a logo is a process that can involve many steps and takes time. We will do our best to reach out to everyone who uses BioNova’s logo in any marketing materials but please contact our marketing officer, Emma Menchefski for the new logo and guidelines if you plan to update any of these materials in the near future. All the best, Scott Moffitt Managing Director]]>
BIONOVA CONTACT
#46 1344 Summer Street
Halifax, Nova Scotia
Canada B3H 0A8
Phone: 902-421-5705
Fax: 902-421-2733
Email: [email protected]
Halifax, Nova Scotia
Canada B3H 0A8
Phone: 902-421-5705
Fax: 902-421-2733
Email: [email protected]

Recent Posts
- MARS VR Lab
- Workinsights
- NEWS RELEASE: BioNova Announces MycoFutures North Atlantic as the Winner of the Eleventh Annual BioInnovation Challenge (BIC) at BioPort 2021
- NEWS RELEASE: BioNova’s BioPort 2021 Conference for Health and Life Sciences Kicks-Off Today
- NEWS RELEASE: BioNova Selects Eight Semi-Finalists to Participate in the 11th Annual BioInnovation Challenge
Business Wire National BioTech News
- Rapid Dose Therapeutics Closes First Tranche of Private Placement
- Antibe Therapeutics Appoints New Board Chair and Corporate Vice Chairs
- Circulating Tumor Cell Market Research Report 2022 - ResearchAndMarkets.com
- First Patients Enrolled in IMPACT II Study to Evaluate Attune Medical’s ensoETM for Radiofrequency Ablation Procedures
- FSD Pharma Issues Circular, Adopts Incentive Plan and Grants PSUs
- Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting
- Miravo Healthcare™ Announces Appointment of Dale MacCandlish Weil to its Board of Directors
- Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference Product Stelara®
- Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress
- Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal
RECENT NEWS
- MARS VR Lab January 25, 2022
- Workinsights January 25, 2022
- NEWS RELEASE: BioNova Announces MycoFutures North Atlantic as the Winner of the Eleventh Annual BioInnovation Challenge (BIC) at BioPort 2021 November 8, 2021
- NEWS RELEASE: BioNova’s BioPort 2021 Conference for Health and Life Sciences Kicks-Off Today November 2, 2021
- NEWS RELEASE: BioNova Selects Eight Semi-Finalists to Participate in the 11th Annual BioInnovation Challenge August 24, 2021
- NEWS RELEASE: BioNova supports the Government of Canada’s biomanufacturing and life sciences strategy July 30, 2021
RECENT TWEETS
Congrats to members @AdaptiivCo on their collaboration deal with printer giant HP 3D Printing and Palo Alto, California medtech specialist Varian. https://t.co/nCJfuIBZXW https://t.co/dYk1Ysyuiy
🎉Congrats to our members Precision BioLogic Inc., leading developers of #hemostasis diagnostic products, on the launch of their new product to improve testing for Hemophilia B
➡️Learn more: https://t.co/l2nsLSTgM7 https://t.co/akuFUMZhzh
➡️Learn more: https://t.co/l2nsLSTgM7 https://t.co/akuFUMZhzh
